Lenacapavir could put the end of the HIV epidemic in reach — if the people who need it can access it. Here’s one way to make ...

Add Yahoo as a preferred source to see more of our stories on Google. Ian L. Haddock founder of the normal anomaly I was born in Galveston County, Texas, the very place where, on June 19, 1865, ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden administration announced October 21. The news comes just weeks after it was announced ...

A recent study has found that lenacapavir, an injectable medication administered twice a year, is more effective at preventing HIV among gay, bisexual, and transgender people than a daily regimen of ...

A recent study of injectable pre-exposure prophylaxis found that twice-yearly injections of lenacapavir — marketed as Yeztugo by Gilead Sciences — do not have clinically significant interactions with ...

The Biden-Harris administration announced Monday a new requirement for insurance providers to cover injectable PrEP in their policies without a co-payment for consumers. The new rule, built on ...

HOUSTON — The fight against HIV has come a long way, and new advancements in prevention are changing the game. One of the latest breakthroughs is a long-lasting injectable form of PrEP (pre-exposure ...

Add Yahoo as a preferred source to see more of our stories on Google. Close up barefoot young gay male couple in pajamas cuddling on bed in morning I haven't taken my pills in two weeks. I went to my ...

LOS ANGELES--(BUSINESS WIRE)--In light of the recently announced plan to put 2.5 million people on injectable pre-exposure prophylaxis (PrEP), specifically lenacapavir, by 2027, AIDS Healthcare ...

Findings showed 99.9% of participants in the lenacapavir group did not acquire HIV infection. Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are complicating the process of getting shots. The new injectable was approved ...

Rwanda's nationwide rollout of long-acting injectable PrEP, Cabotegravir, marks a significant step forward in the fight against HIV/AIDS. However, this development highlights a deeper truth: ending ...